IDEAS home Printed from https://ideas.repec.org/a/eee/ecanpo/v83y2024icp734-748.html

Can the separation of marketing authorization from manufacturing authorization stimulate pharmaceutical innovation? Evidence from China's pharmaceutical industry reform

Author

Listed:
  • Wan, Paijie
  • He, Feng
  • Zhang, Hongjie

Abstract

Using data from A-share pharmaceutical manufacturing listed companies between 2011 and 2021, this paper constructs a difference in differences (DID) model to systematically analyze the impact of China's Marketing Authorization Holder (MAH) system pilot policy on pharmaceutical enterprise innovation. Our findings indicate that implementing the MAH system can significantly stimulate innovation in pharmaceutical enterprises, both in terms of input and output. Additionally, local intellectual property protection positively moderates the incentive effect of MAH system on pharmaceutical innovation. The results of our heterogeneity analysis further demonstrate that the pilot policy of the MAH system exerts a stronger incentive effect on the innovation behavior of non-state-owned enterprises and enterprises in the growth and mature stage. Moreover, we provide evidence for the long-term impact of MAH system on innovation within pharmaceutical companies.

Suggested Citation

  • Wan, Paijie & He, Feng & Zhang, Hongjie, 2024. "Can the separation of marketing authorization from manufacturing authorization stimulate pharmaceutical innovation? Evidence from China's pharmaceutical industry reform," Economic Analysis and Policy, Elsevier, vol. 83(C), pages 734-748.
    • Handle: RePEc:eee:ecanpo:v:83:y:2024:i:c:p:734-748
    DOI: 10.1016/j.eap.2024.07.020
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0313592624001875
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.eap.2024.07.020?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to

    for a different version of it.

    References listed on IDEAS

    as
    1. Shahzad, Farrukh & Ahmad, Munir & Fareed, Zeeshan & Wang, Zhenkun, 2022. "Innovation decisions through firm life cycle: A new evidence from emerging markets," International Review of Economics & Finance, Elsevier, vol. 78(C), pages 51-67.
    2. Zhang, Xuan & Nie, Huihua, 2021. "Public health insurance and pharmaceutical innovation: Evidence from China," Journal of Development Economics, Elsevier, vol. 148(C).
    3. Roper, Stephen & Hewitt-Dundas, Nola, 2008. "Innovation persistence: Survey and case-study evidence," Research Policy, Elsevier, vol. 37(1), pages 149-162, February.
    4. Zhengwen Lu & Yujie Zhang & Yuanxu Li, 2022. "Strategic Charitable Giving and R&D Innovation of High-Tech Enterprises: A Dynamic Perspective Based on the Corporate Life Cycle," Sustainability, MDPI, vol. 14(23), pages 1-20, December.
    5. Xiubao Yu & Jie Yan & Dimitris Assimakopoulos, 2015. "Case analysis of imitative innovation in Chinese manufacturing SMEs : Products, features, barriers and competences for transition," Grenoble Ecole de Management (Post-Print) hal-02313377, HAL.
    6. Bu, Maoliang & Qiao, Zhenzi & Liu, Beibei, 2020. "Voluntary environmental regulation and firm innovation in China," Economic Modelling, Elsevier, vol. 89(C), pages 10-18.
    7. Chen, Jin & Heng, Cheng Suang & Tan, Bernard C.Y. & Lin, Zhijie, 2018. "The distinct signaling effects of R&D subsidy and non-R&D subsidy on IPO performance of IT entrepreneurial firms in China," Research Policy, Elsevier, vol. 47(1), pages 108-120.
    8. Juan-José Ganuza & Gerard Llobet & Beatriz Domínguez, 2009. "R& D in the Pharmaceutical Industry: A World of Small Innovations," Management Science, INFORMS, vol. 55(4), pages 539-551, April.
    9. Dimitrios Kourouklis, 2021. "Public subsidies for R&D and public sector pharmaceutical innovation," Applied Economics, Taylor & Francis Journals, vol. 53(32), pages 3759-3777, July.
    10. Long, Houyin & Wu, Zhifeng & Huang, Xiang & Wang, Jiaxin & Zhang, Qihao, 2023. "The deleveraging puzzle of investment opportunity shock: A quasi-natural experiments on drug marketing authorization holder," International Review of Financial Analysis, Elsevier, vol. 90(C).
    11. Grossmann, Volker, 2013. "Do cost-sharing and entry deregulation curb pharmaceutical innovation?," Journal of Health Economics, Elsevier, vol. 32(5), pages 881-894.
    12. Yu, Xiubao & Yan, Jie & Assimakopoulos, Dimitris, 2015. "Case analysis of imitative innovation in Chinese manufacturing SMEs: Products, features, barriers and competences for transition," International Journal of Information Management, Elsevier, vol. 35(4), pages 520-525.
    13. Liu, Yun & Gao, Qun, 2024. "Economic policy uncertainty and enterprise innovation in China: From the perspective of equity financing and financing structure," Economic Analysis and Policy, Elsevier, vol. 81(C), pages 17-33.
    14. Dimitrios Kourouklis, 2021. "Public subsidies for R&D and public sector pharmaceutical innovation," Post-Print hal-03154800, HAL.
    15. Jacobson, Louis S & LaLonde, Robert J & Sullivan, Daniel G, 1993. "Earnings Losses of Displaced Workers," American Economic Review, American Economic Association, vol. 83(4), pages 685-709, September.
    16. Huang, Zhi-xiong & Yang, Xiandong, 2021. "Carbon emissions and firm innovation," Economic Analysis and Policy, Elsevier, vol. 69(C), pages 503-513.
    17. Jiyeon Yoo & Sangryul Lee & Sambock Park, 2019. "The Effect of Firm Life Cycle on the Relationship between R&D Expenditures and Future Performance, Earnings Uncertainty, and Sustainable Growth," Sustainability, MDPI, vol. 11(8), pages 1-19, April.
    18. Jian Zhou & Rong Qin & Xin Wang & Shunhao Wang, 2023. "Does directors’ innovation experience promote firm innovation? Evidence from China," Knowledge Management Research & Practice, Taylor & Francis Journals, vol. 21(3), pages 537-550, May.
    19. Geng, Hao & Shi, Ce Matthew, 2024. "Health policy, price regulation, and innovation: Evidence from China’s vaccine industry," Journal of Development Economics, Elsevier, vol. 167(C).
    20. Li, Xiuzhen & Sun, Yuchen & Long, Zhi & Wang, Qian, 2024. "The impact of venture capital on the development of medical and healthcare industry: Empirical analysis of Chinese A-share pharmaceutical companies," Pacific-Basin Finance Journal, Elsevier, vol. 85(C).
    21. Mark Armstrong & John Vickers, 1991. "Welfare Effects of Price Discrimination by a Regulated Monopolist," RAND Journal of Economics, The RAND Corporation, vol. 22(4), pages 571-581, Winter.
    22. Yang, Tingting & Xu, Botong, 2023. "Incentive effects of government subsidy on technological innovation: Evidence from pharmaceutical industry," Finance Research Letters, Elsevier, vol. 55(PA).
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Zilong Wang & Hechang Cai, 2025. "Competing Through Innovation in Networked Manufacturing," International Journal of Strategic Decision Sciences (IJSDS), IGI Global Scientific Publishing, vol. 15(1), pages 1-29, January.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Liu, Duan & Yu, Nizhou & Wan, Hong, 2022. "Does water rights trading affect corporate investment? The role of resource allocation and risk mitigation channels," Economic Modelling, Elsevier, vol. 117(C).
    2. Wang, Weilong & Wang, Jianlong & Wu, Haitao, 2024. "The impact of energy-consuming rights trading on green total factor productivity in the context of digital economy: Evidence from listed firms in China," Energy Economics, Elsevier, vol. 131(C).
    3. Li, Changsong & Cao, Xiaojing & Wang, Zeyu & Zhang, Jiali & Liu, Huan, 2025. "The impact of green bond issuance on corporate green innovation: A signaling perspective," International Review of Financial Analysis, Elsevier, vol. 102(C).
    4. Ying, Wenchi & Pee, Loo Geok & Jia, Suling, 2018. "Social informatics of intelligent manufacturing ecosystems: A case study of KuteSmart," International Journal of Information Management, Elsevier, vol. 42(C), pages 102-105.
    5. Gentilini, Arianna & Miraldo, Marisa, 2023. "The role of patient organisations in research and development: Evidence from rare diseases," Social Science & Medicine, Elsevier, vol. 338(C).
    6. Chen, Ning & Yan, Nan & Xie, Henglang & Ou, Yifan, 2024. "Impact of media attention on corporate green innovation: What is the role of dual environmental regulation?," International Review of Financial Analysis, Elsevier, vol. 96(PA).
    7. Liang, Shuzhen & Ye, Yongwei & Zhang, Ruifeng, 2025. "Social credit system and the alleviation of investment–financing maturity mismatch in China," Economic Analysis and Policy, Elsevier, vol. 87(C), pages 1415-1435.
    8. Yexin Liu & Weiwei Wu & Yanggi Kim, 2023. "How do latecomer firms achieve catch-up through technology management: a comparative analysis," Humanities and Social Sciences Communications, Palgrave Macmillan, vol. 10(1), pages 1-12, December.
    9. Oliver, Edward & Kourouklis, Dimitrios & Jofre-Bonet, Mireia, 2024. "Do R&D tax credits impact pharmaceutical innovation? Evidence from a synthetic control approach," Research Policy, Elsevier, vol. 53(8).
    10. Keqiang Wang & Chunxin Lin, 2024. "Can Low-Carbon Transition Impact the High-Quality Development of the Manufacturing Industry?—Experience Evidence from a Low-Carbon Pilot Policy," Sustainability, MDPI, vol. 16(23), pages 1-27, December.
    11. Volker Grossmann, 2021. "Medical Innovations and Ageing: A Health Economics Perspective," CESifo Working Paper Series 9387, CESifo.
    12. Yanping Xu & Lilong Zhu, 2022. "Pharmaceutical Enterprises’ R&D Innovation Cooperation Moran Strategy When Considering Tax Incentives," IJERPH, MDPI, vol. 19(22), pages 1-13, November.
    13. Massimo Florio & Chiara Pancotti, 2022. "European pharmaceutical research and development. Could a public infrastructure overcome market failures?," Working Papers 202202, CSIL Centre for Industrial Studies.
    14. Bas Scheer & Wiljan van den Berge & Maarten Goos & Alan Manning & Anna Salomons, 2022. "Alternative Work Arrangements and Worker Outcomes: Evidence from Payrolling," CPB Discussion Paper 435, CPB Netherlands Bureau for Economic Policy Analysis.
    15. Yuegang Song & Songlin Jin & Zhenhui Li, 2022. "Venture Capital and Chinese Firms’ Technological Innovation Capability: Effective Evaluation and Mechanism Verification," Sustainability, MDPI, vol. 14(16), pages 1-20, August.
    16. Ye, Dezhu & Ji, Wenjun & Sun, Nan, 2025. "Corporate diversification strategies and bankruptcy risk: A re-examination based on COVID-19," Journal of Asian Economics, Elsevier, vol. 99(C).
    17. Alexander Hijzen & Sébastien Jean & Thierry Mayer, 2011. "The effects at home of initiating production abroad: evidence from matched French firms," Review of World Economics (Weltwirtschaftliches Archiv), Springer;Institut für Weltwirtschaft (Kiel Institute for the World Economy), vol. 147(3), pages 457-483, September.
    18. David Card, 2022. "Design-Based Research in Empirical Microeconomics," American Economic Review, American Economic Association, vol. 112(6), pages 1773-1781, June.
    19. Alan B. Krueger & Douglas Kruse, 1995. "Labor Market Effects of Spinal Cord Injuries in the Dawn of the Computer Age," Working Papers 728, Princeton University, Department of Economics, Industrial Relations Section..
    20. Laiqun Jin & Xiuyan Liu & Sam Hak Kan Tang, 2021. "High-Technology Zones, Misallocation of Resources among Cities and Aggregate Productivity: Evidence from China," Economics Discussion / Working Papers 21-11, The University of Western Australia, Department of Economics.

    More about this item

    Keywords

    ;
    ;
    ;

    JEL classification:

    • L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology; Plastics
    • R50 - Urban, Rural, Regional, Real Estate, and Transportation Economics - - Regional Government Analysis - - - General

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:ecanpo:v:83:y:2024:i:c:p:734-748. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.journals.elsevier.com/economic-analysis-and-policy .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.